논문 상세보기
pp.7-11
To evaluate the outcome, clinical efficacy and safety of endometrial heat balloons therapy by Thermachoice® for the treatment of heavy menstruation. From June 2004 to December 2014, a total of 120 women who visited to Chosun University Hospital had their charts and telephones reviewed for demographics, procedure data, clinical history, and follow up. The mean age was 43.5±4.7 years old. A decrease in days per cycle (7.5±2.1 vs 5.6±2.4 days, p<0.001), and in pads per day (9.1±2.5 vs 5.5±3.4 pads/d, p<0.001) and an increase in hematocrit (%, mean±SD) (7.1±0.6)/ hemoglobin (g/dL, mean±SD) (7.1±0.6 / 28.7±2.3 vs 11.5±1.4 / 35.9±4.1, p<0.001) and an improvement in self-reported quality of life scores (limitation of life: 7.4±2.3 vs 2.4±1.5, p<0.0001, discomfort score: 1.8±1.4 vs 0.7±1.2, p<0.001) were observed after endometrial heat balloons therapy. No major complications or deaths were found. Assessment of the level of satisfaction showed that 86% of patients were satisfied with the procedure. The prognostic factors of endometrial heat balloons therapy were age, parity, uterine pressure and depth, position. But age and uterine pressure had no significant difference statistically. Endometrial heat balloons therapy by Thermachoice® is a safe and efficient method to treat of heavy menstruation. It reduces the menstrual flow, improves the quality of life, and remarkably satisfies patients with a desire to preserve a uterus
